Paolo Bettica MD, PhD

Paolo Bettica is an Italian physician with a PhD in Pharmacology and Toxicology and a specialization in Clinical Pharmacology. In 1996, after more than 10 years in academia and hospital, he started working in Pharmaceutical companies where he has worked in all phases of Clinical Development from Phase 1 to Phase 4 and in different therapeutic areas such as Neuroscience, Pain, Rheumatology, Endocrinology, Oncology, Rare Diseases. During this time, he has successfully taken 10 NCEs into humans, he has successfully taken 4 NCEs through Proof of Concept (1 in Social Anxiety Disorder, 1 in Depression, 1 in Primary Insomnia, and 1 in Oncology), he has led the Phase III development in Europe of a disease modifying drug in Osteoarthritis and he was a member of the submission team in Europe for Actonel in Osteoporosis and Teglutik in Amyotrophic Lateral Sclerosis. Leading the Clinical Research and Development department of Italfarmaco he is responsible for the development of the pipeline of NCEs and NMEs up to market in different therapeutic areas such as Rare Diseases, Oncology, Muscle and Neuro Degeneration, Cardiovascular. These compounds are currently at different stages of development from Phase I till registration.